PPDC Meeting: Endocrine Disruptor Screening Program Update

First Page		Document Content
Date: 2014-05-29 09:51:49 Intracellular receptors Transcription factors Endocrine disruptor Estrogen Endocrine system Puberty Hormone Androgen receptor Biology Cell biology Endocrinology		PPDC Meeting: Endocrine Disruptor Screening Program Update Add to Reading List Source URL: www2.epa.gov Download Document from Source Website File Size: 716,91 KB Share Document on Facebook

	Abstract # 3991 Novel small molecule inhibitor of p300/CBP down-regulates androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond CellCentric DocID: 1vi4a - View Document
	Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol7Issue4abst086P.pdf Using the fluorescent antagonist, XAC-X-BY630 to quantify antagonist-adenosine A3 receptor complexes in mem DocID: 1qBQB - View Document
	SpringHAUPTMAN-WOODWARD INSTITUTE An Independent Non-Profit Biomedical Research Institute PROSTATE CANCER is the most frequently diagnosed male cancer. DocID: 1pTiN - View Document
	Application examples for the Mammalian-2-Hybrid system M2H - Liver X Receptor alpha (LXRa) plus NCoA3 and Liver X Receptor alpha plus NCoR with control agonist T0901317 M2H - Androgen Receptor (AR) plus NCoA3 with contr DocID: 1nxYE - View Document
	Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer Xiaochuan Shan1 , Gwenn Danet-Desnoyers1 , Juan Jos´e Fung2 , Alan H. Kosaka2 , Fraser Tan3 , Nicole Perfito3 , Joelle DocID: 1lWYj - View Document